CA3028036A1 - Compounds for treating disorders sensitive to serotoninergic regulation controlled by the 5-ht1a receptors - Google Patents

Compounds for treating disorders sensitive to serotoninergic regulation controlled by the 5-ht1a receptors Download PDF

Info

Publication number
CA3028036A1
CA3028036A1 CA3028036A CA3028036A CA3028036A1 CA 3028036 A1 CA3028036 A1 CA 3028036A1 CA 3028036 A CA3028036 A CA 3028036A CA 3028036 A CA3028036 A CA 3028036A CA 3028036 A1 CA3028036 A1 CA 3028036A1
Authority
CA
Canada
Prior art keywords
compound
nmr
cdci3
methyl
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3028036A
Other languages
English (en)
French (fr)
Inventor
Joanna SNIECIKOWSKA
Adam Bucki
Adrian Newman-Tancredi
Mark Andrew Varney
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Neurolixis
Universite Jagellonne
Original Assignee
Neurolixis
Universite Jagellonne
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurolixis, Universite Jagellonne filed Critical Neurolixis
Publication of CA3028036A1 publication Critical patent/CA3028036A1/en
Pending legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/38Halogen atoms or nitro radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
CA3028036A 2016-06-24 2017-06-23 Compounds for treating disorders sensitive to serotoninergic regulation controlled by the 5-ht1a receptors Pending CA3028036A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16305769.8 2016-06-24
EP16305769.8A EP3260452A1 (en) 2016-06-24 2016-06-24 Compounds for treating disorders sensitive to serotoninergic regulation controlled by the 5-ht1a receptors
PCT/EP2017/065585 WO2017220799A1 (en) 2016-06-24 2017-06-23 Compounds for treating disorders sensitive to serotoninergic regulation controlled by the 5-ht1a receptors

Publications (1)

Publication Number Publication Date
CA3028036A1 true CA3028036A1 (en) 2017-12-28

Family

ID=56404042

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3028036A Pending CA3028036A1 (en) 2016-06-24 2017-06-23 Compounds for treating disorders sensitive to serotoninergic regulation controlled by the 5-ht1a receptors

Country Status (9)

Country Link
US (1) US10562853B2 (enExample)
EP (2) EP3260452A1 (enExample)
JP (1) JP6935873B2 (enExample)
CN (1) CN109563073B (enExample)
AU (1) AU2017281742B2 (enExample)
CA (1) CA3028036A1 (enExample)
DK (1) DK3475268T3 (enExample)
ES (1) ES2831853T3 (enExample)
WO (1) WO2017220799A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119874616B (zh) * 2025-03-28 2025-05-30 四川美域高生物医药科技有限公司 一种有机中间体及其制备方法和应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2702211B1 (fr) * 1993-03-04 1995-06-02 Pf Medicament Nouveaux dérivés de la phénoxy-2 éthylamine, leur préparation et leur application en thérapeutique.
FR2755967B1 (fr) * 1996-11-21 1999-01-29 Pf Medicament Derives de la pyridin-2-yl-methylamine, leur procede de preparation et leur application comme medicaments
FR2784378B1 (fr) * 1998-10-09 2000-12-29 Pf Medicament Nouveaux derives d'aryl-(4-fluoro-4-[(2-pyridin-2-yl- ethylamino)-methyl]-piperidin-1-yl)-methanone, leur procede de preparation et leur utilisation a titre de medicaments
EP2058306A1 (en) * 2007-11-08 2009-05-13 Schwarz Pharma Ag Heteroaryl-substituted 2-pyridinyl-methylamine derivatives
PL395470A1 (pl) * 2011-06-29 2013-01-07 Adamed Spólka Z Ograniczona Odpowiedzialnoscia Sulfonamidowe pochodne amin alicyklicznych do leczenia chorób osrodkowego ukladu nerwowego

Also Published As

Publication number Publication date
JP2019519615A (ja) 2019-07-11
US20190194132A1 (en) 2019-06-27
WO2017220799A1 (en) 2017-12-28
US10562853B2 (en) 2020-02-18
AU2017281742B2 (en) 2021-01-07
EP3475268B9 (en) 2021-04-21
EP3260452A1 (en) 2017-12-27
JP6935873B2 (ja) 2021-09-15
AU2017281742A1 (en) 2019-01-03
DK3475268T3 (da) 2020-10-26
EP3475268A1 (en) 2019-05-01
ES2831853T3 (es) 2021-06-09
CN109563073A (zh) 2019-04-02
CN109563073B (zh) 2021-12-07
EP3475268B1 (en) 2020-08-19

Similar Documents

Publication Publication Date Title
JP5335932B2 (ja) 制癌剤である二置換ピリジン誘導体
KR102566864B1 (ko) 아릴- 또는 헤테로아릴-치환된 벤젠 화합물
US7645778B2 (en) Heteroaryl compounds as P2Y1 receptor inhibitors
CN103717593B (zh) 调节激酶的组合物和方法
KR20140034787A (ko) 치환된 벤젠 화합물
JP2014511389A (ja) 置換6,5−縮合二環式ヘテロアリール化合物
US9278933B2 (en) Synthesis of a neurostimulative piperazine
MX2014012991A (es) Derivado de benzamida.
US11878968B2 (en) Aryl compounds and pharmaceutical compositions that modulate IKZF2
WO2014022253A1 (en) Amino-heteroaryl 7-hydroxy-spiropiperidine indolinyl antagonists of p2y1 receptor
JP2013047223A (ja) 医薬
AU2017281742B2 (en) Compounds for treating disorders sensitive to serotoninergic regulation controlled by the 5-HT1A receptors
WO2022240992A1 (en) Heterocyclic trpml1 agonists and uses thereof
HK40007735A (en) Compounds for treating disorders sensitive to serotoninergic regulation controlled by the 5-ht1a receptors
HK40007735B (en) Compounds for treating disorders sensitive to serotoninergic regulation controlled by the 5-ht1a receptors
Frazier et al. Synthesis of diversely substituted pyridin-2 (1 H)-ones and in vivo evaluation of their anti-allodynic effect on cutaneous inflammatory mechanical allodynia
NZ793902A (en) Substituted 2-azabicycles and their use as orexin receptor modulators
KR20240046553A (ko) Sting 길항제로서의 소분자 우레아 유도체

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220609

EEER Examination request

Effective date: 20220609

EEER Examination request

Effective date: 20220609

EEER Examination request

Effective date: 20220609

EEER Examination request

Effective date: 20220609

EEER Examination request

Effective date: 20220609

EEER Examination request

Effective date: 20220609